Rheumatology: a force for change in monoclonal antibodies.

Abstract:

:Monoclonal antibodies have undergone a radical evolutionary journey over the last 25 years, with advances in molecular biology, process development and drug formulation underpinning their rise to becoming one of the most efficacious and economically important class of drug today. The success of antibodies for the treatment of rheumatological conditions, such as rheumatoid arthritis in particular, has driven the biopharmaceutical industry to optimize all aspects of therapeutic antibody discovery and development, in order to provide further benefits for patients over and above marketed treatments, via increased clinical efficacy and patient convenience. Recent advances in many of the key aspects of antibody design that are driving this evolution, such as affinity optimization, effector function modulation, pharmacokinetic engineering, as well as developments in subcutaneous drug delivery, are reviewed here.

journal_name

Curr Pharm Des

authors

Lowe DC,Vaughan TJ

doi

10.2174/1381612821666150310142202

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

2179-86

issue

17

eissn

1381-6128

issn

1873-4286

pii

CPD-EPUB-65792

journal_volume

21

pub_type

杂志文章,评审
  • Agonist replacement for stimulant dependence: a review of clinical research.

    abstract::Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and cl...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161281940131209142843

    authors: Stoops WW,Rush CR

    更新日期:2013-01-01 00:00:00

  • Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments.

    abstract:BACKGROUND:Central serous chorioretinopathy (CSC) is the fourth most frequent retinal disorder in terms of prevalence. It typically occurs in young subjects and affects men more often than women. CSC is characterized by serous retinal detachment (SRD) involving mainly the macular area. The clinical course is usually se...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666190123165914

    authors: Iacono P,Toto L,Costanzo E,Varano M,Parravano MC

    更新日期:2018-01-01 00:00:00

  • Do substance P and the NK1 receptor have a role in depression and anxiety?

    abstract::Research on Substance P (SP) has, until recently, focused on its role in pain and inflammation. However, a report that NK(1) receptor antagonists have utility in the treatment of depression has stimulated research into the function of SP and the NK(1)receptor in anxiety and depression. The distribution of SP and the N...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612053764779

    authors: McLean S

    更新日期:2005-01-01 00:00:00

  • Opiate-induced analgesia: contributions from mu, delta and kappa opioid receptors mouse mutants.

    abstract::The three opioid receptors, mu, delta and kappa all mediate analgesia, and knockout mice with opioid receptor deletion have proven unique tools to investigate in vivo opioid pharmacology. Since a few years, a number of new mouse lines have been engineered, with several distinct mutations of the mu receptor, to assess ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161281942140105163727

    authors: Gavériaux-Ruff C

    更新日期:2013-01-01 00:00:00

  • Rationale for Ras and raf-kinase as a target for cancer therapeutics.

    abstract::Improvements in our understanding of the intrinsic aberrancies in cancer cells have enabled the design and development of novel therapeutics that specifically target these changes. Among the many complex cellular pathways and mechanisms which have been unveiled by new molecular techniques, RAS-mediated signal transduc...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612023393107

    authors: Nottage M,Siu LL

    更新日期:2002-01-01 00:00:00

  • New strategies in the development of antidepressants: towards the modulation of neuroplasticity pathways.

    abstract::Over the past five decades, the pharmacological treatment of depression has been based on the pathophysiological hypothesis of a deficiency in monoamines, mainly serotonin and noradrenaline. Antidepressant prescribed today, all of them designed to enhance central monoaminergic tone, present several important limitatio...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211795164086

    authors: Vidal R,Pilar-Cuéllar F,dos Anjos S,Linge R,Treceño B,Vargas VI,Rodriguez-Gaztelumendi A,Mostany R,Castro E,Diaz A,Valdizán EM,Pazos A

    更新日期:2011-01-01 00:00:00

  • Nanoparticles in Ocular Drug Delivery Systems for Topical Administration: Promises and Challenges.

    abstract::The majority of pharmaceutical formulations for the treatment of ocular pathologies are for topical administration. However, this kind of ophthalmic formulations has disadvantages such as low bioavailability and, consequently, a reduced therapeutic effect. This happens due to the anatomical and physiological specifici...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150923095155

    authors: Almeida H,Amaral MH,Lobao P,Frigerio C,Sousa Lobo JM

    更新日期:2015-01-01 00:00:00

  • AMPA receptor antagonists with additional mechanisms of action: new opportunities for neuroprotective drugs?

    abstract::Ischaemic stroke of the brain accounts for about one third of all deaths in industrialized countries. Many of the patients who survive are severily impaired. Thus, there is an enormous need for pharmacotherapy for the treatment of ischaemic stroke. Why is such a treatment not available yet? Are the pathophysiological ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612024607135

    authors: Weiser T

    更新日期:2002-01-01 00:00:00

  • Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?

    abstract:BACKGROUND:Polycystic ovary syndrome (PCOS) is a frequent female reproductive endocrine disease. It has been associated with a number of severe reproductive and metabolic abnormalities. However, there are still open questions especially regarding the best long-term management. METHODS:We summarized the literature focu...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666190130104922

    authors: Ruan X,Li M,Mueck AO

    更新日期:2018-01-01 00:00:00

  • Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly accounts for clinical dementia. Inflammation plays a key role in AD and dissecting the genetics of inflammation may provide an answer to the possible treatment. Hence, the better understanding of diffe...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161208786264089

    authors: Balistreri CR,Grimaldi MP,Chiappelli M,Licastro F,Castiglia L,Listì F,Vasto S,Lio D,Caruso C,Candore G

    更新日期:2008-01-01 00:00:00

  • Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature.

    abstract::Both high arterial blood pressure (BP) and elevated levels of fine particulate matter (PM2.5) air pollution have been associated with an increased risk for several cardiovascular (CV) diseases, including stroke, heart failure, and myocardial infarction. Given that PM2.5 and high BP are each independently leading risk ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666151109111712

    authors: Giorgini P,Di Giosia P,Grassi D,Rubenfire M,Brook RD,Ferri C

    更新日期:2016-01-01 00:00:00

  • Mobile Health Applications for Prenatal Assessment and Monitoring.

    abstract:BACKGROUND:A mobile health application is an exciting, fast-paced domain that is likely to improve prenatal care. METHODS:In this narrative review, we summarise the use of mobile health applications in this setting with a special emphasis on both the benefits of remote monitoring devices and the potential pitfalls of ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666190320140659

    authors: Gyselaers W,Lanssens D,Perry H,Khalil A

    更新日期:2019-01-01 00:00:00

  • TNF(alpha) modulation of visceral and spinal sensory processing.

    abstract::The cytokine tumor necrosis factor(alpha) (TNF(alpha)) is associated with a constellation of physiological and behavioral characteristics that follow in response to infection such as fever, fatigue, listlessness, loss of appetite, malaise, and tactile hypersensitivity. These responses are examples of central nervous s...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612053507828

    authors: Hermann GE,Holmes GM,Rogers RC

    更新日期:2005-01-01 00:00:00

  • The role of niacin in lipid-lowering treatment: are we aiming too high?

    abstract::The clinically most relevant medications for lipid management are the statins, which constitute in the majority of the cases the basis of any lipid-modulating therapy. However, other agents are often needed to either reduce low-density cholesterol to target levels and/or to treat residual serum lipoprotein abnormaliti...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612811319170017

    authors: Gouni-Berthold I,Berthold HK

    更新日期:2013-01-01 00:00:00

  • Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?

    abstract::Type 2 diabetes is associated with substantially increased cardiovascular mortality. The need to reduce the progression of atherosclerosis alongside lowering blood glucose levels is now well established. Ideally, pharmaceutical treatment should address both of these needs. This review summarises current evidence of th...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209789057995

    authors: Papanas N,Maltezos E

    更新日期:2009-01-01 00:00:00

  • Nuclear Medicine Imaging in Fever of Unknown Origin: The New Paradigm.

    abstract::Fever of Unknown Origin, or FUO, is a challenging condition for patients and clinicians. In up to 50% of cases, no diagnosis is established. Patient workup begins with comprehensive history, physical examination and laboratory tests. Radionuclide imaging has been a second-line procedure. Gallium-67 citrate, which accu...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612824666171129194507

    authors: Palestro CJ,Love C

    更新日期:2018-01-01 00:00:00

  • The impact of traditional plants and their secondary metabolites in the discovery of COVID-19 treatment.

    abstract:BACKGROUND:Coronavirus Disease-2019 belongs to the family of viruses which cause a serious pneumonia along with fever, breathing issues and infection of lungs for the first time in China and later spread worldwide. OBJECTIVE:Several studies and clinical trials have been conducted to identify potential drugs and vaccin...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666201118103416

    authors: Bibi S,Sarfraz A,Mustafa G,Ahmed Z,Zeb MA,Wang YB,Khan T,Khan MS,Kamal MA,Yu H

    更新日期:2020-11-17 00:00:00

  • Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis.

    abstract::During the last decade immunomodulatory treatments have been shown to influence the natural course of multiple sclerosis (MS). However, demyelination in the central nervous system (CNS) still occurs and repair mechanisms are incomplete leading to neurological deficits. Currently, there is no therapy available to promo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206775193118

    authors: Trebst C,Stangel M

    更新日期:2006-01-01 00:00:00

  • Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets.

    abstract::The development of targeted therapy drugs acting on tumor growth and progression is greatly expanding these last years. Among them kinase inhibitors have a prominent position and have demonstrated efficacy and clinical benefits in solid and hematologic malignancies. Compared to conventional systemic cytotoxic chemothe...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666160226132630

    authors: Levade M,Severin S,Gratacap MP,Ysebaert L,Payrastre B

    更新日期:2016-01-01 00:00:00

  • Gene Delivery with Organic Electronic Biomaterials.

    abstract::Gene therapy may be capable of treating a variety of diseases, a prerequisite of which is the successful delivery of polynucleic acids (e.g., DNA, RNA) to a patient's cells. Delivery can be achieved technologically (e.g., using electroporation), using viruses (natural gene delivery vectors) or non-viral vectors (e.g.,...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612823666170710124137

    authors: Clancy KFA,Hardy JG

    更新日期:2017-01-01 00:00:00

  • Design of multivalent ligand targeting G-protein-coupled receptors.

    abstract::More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209787315639

    authors: Liu Z,Zhang J,Zhang A

    更新日期:2009-01-01 00:00:00

  • A Combination of Ulinastatin and Xuebijing Amplifies Neuroprotection after Transient Cerebral Ischemia via Attenuating Apoptosis Signal Pathways in Hippocampus.

    abstract:BACKGROUND:Ulinastatin (UTI) plays the beneficial roles in modifying cerebral ischemic injury evoked by cardiac arrest (CA). XueBiJing (XBJ), comprised of extracts from Chinese herbals, has been used for the treatment of sepsis and ischemic disorders linked to multiple organ dysfunction syndromes. The current study was...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612825666190206224134

    authors: Ma C,Han DF,Jin H,Cheng YY,Hu HX,Wang X

    更新日期:2018-01-01 00:00:00

  • Soft Biomaterial-based Nanocrystal in Pharmaceutical.

    abstract:BACKGROUND AND OBJECTIVE:Bio-soft material, a class of derivatives of the natural or synthetic material, is getting more and more prevalent in biomedical researches and applications due to the advantages such as in-vivo biodegradation, good water solubility and designable targeting ability. With the presence of bio-sof...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612824666180515154848

    authors: Chen N,Su T,Cheng Z,An F

    更新日期:2018-01-01 00:00:00

  • Photodynamic Therapy of Psoriasis Using Photosensitizers of Vegetable Origin.

    abstract::Psoriasis is an immune-mediated, chronic and recurrent inflammatory skin disease, prevalent worldwide, and represents an important burden in life quality of patients. The most common clinical variant is termed as psoriasis vulgaris or plaque psoriasis, which with an individualized and carefully monitored therapy can d...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666190618122024

    authors: Bruschi ML,da Silva JB,Rosseto HC

    更新日期:2019-01-01 00:00:00

  • Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy.

    abstract::After years of pre-clinical and clinical testing monoclonal antibodies (mAbs) finally offer new therapeutic choices for patients with haematological and solid malignancies both as unconjugated antibody and as vectors to target radionuclides in radioimmunotherapy (RIT). In recent years some of the most exciting clinica...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612003399257

    authors: Illidge TM,Brock S

    更新日期:2000-09-01 00:00:00

  • The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses.

    abstract::Unlike other neuroinflammatory disorders, like Parkinson's disease, Huntington's disease and multiple sclerosis, little is still known of the role of the endocannabinoid system in Alzheimer's disease (AD). This is partly due to the poor availability of animal models that are really relevant to the human disease, and t...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208785740027

    authors: Bisogno T,Di Marzo V

    更新日期:2008-01-01 00:00:00

  • Novel therapeutic approaches to autoimmune demyelinating disorders.

    abstract::Multiple Sclerosis (MS) is the most common autoimmune demyelinating disorder in Western countries and can lead to permanent disability. Over the past decades remarkable progress has been made in providing new therapeutic strategies to tackle the burden of the disease. Oral drugs and monoclonal antibodies are the main ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211798157630

    authors: Sanvito L,Constantinescu CS,Gran B

    更新日期:2011-01-01 00:00:00

  • Polymer Particulates in Drug Delivery.

    abstract::Development of effective drug delivery systems is important for medicine and healthcare. Polymer particulates (micro- and nanoparticles) have opened new opportunities in the field of drug delivery by overcoming various limitations of conventional delivery methods. The properties of polymeric particles can be readily t...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666160217125734

    authors: Kaur H,Kumar V,Kumar K,Rathor S,Kumari P,Singh J

    更新日期:2016-01-01 00:00:00

  • Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy.

    abstract::By updating John Littleton's work published 15 years ago this review summarizes recent work on pharmacodynamic aspects of acamprosate and the perspective for future developments. In addition to insights into the role of glutamatergic receptor systems, craving and relapse inspired by acamprosate, clinical research poin...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210791516341

    authors: Kiefer F,Mann K

    更新日期:2010-01-01 00:00:00

  • Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms.

    abstract::We have synthesized a novel series of N-substituted sarcosines, analogues of NFPS (N-[3-(biphenyl-4- yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine), as type-1 glycine transporter (GlyT-1) inhibitors. Several compounds incorporated a diazine ring inhibited recombinant hGlyT-1b expressed permanently in CHO cells and ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612821666150109125623

    authors: Harsing LG Jr,Timar J,Szabo G,Udvari S,Nagy KM,Marko B,Zsilla G,Czompa A,Tapolcsanyi P,Kocsis A,Matyus P

    更新日期:2015-01-01 00:00:00